Latest news with #ManagementInformationCircular
Yahoo
4 hours ago
- Business
- Yahoo
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the 'Board') at the Meeting and listed in the Company's Management Information Circular dated April 25, 2025, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are elected or appointed. The results of the vote on the election of the Board are as follows: Board of Directors Votes in Favour Votes Withheld Number of Votes Percentage (%) Number of Votes Percentage (%) James A. Helliwell 17,880,699 99.997 505 0.003 Simon Pimstone 16,123,679 90.171 1,757,475 9.829 Richard M. Glickman 17,879,949 99.993 1,255 0.007 Paul Geyer 17,680,609 98.878 200,595 1.122 John Montalbano 17,876,501 99.974 4,703 0.026 Michael Wilmink 17,876,508 99.974 4,696 0.026 Joseph Freedman 17,880,699 99.997 505 0.003 The other items of business at the Meeting were to (i) re-appoint KPMG LLP as the auditor of the Company for the ensuing year and to authorize the Board to fix the remuneration of the auditors; (ii) approve the Company's 2025 Omnibus Incentive Plan; and (iii) approve the re-pricing of certain stock options previously granted to certain non-executive employees, none of which are insiders of the Company, under the Company's amended and restated stock option plan. All such items of business were passed by the shareholders at the Meeting. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", 'suggests', "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products, and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy its our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company's API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact:Danielle Egan, Eupraxia Pharmaceuticals Inc.778.401.3302degan@ or Kevin Gardner, on behalf of:Eupraxia Pharmaceuticals Inc.617.283.2856kgardner@ SOURCE Eupraxia Pharmaceuticals in to access your portfolio
Yahoo
5 hours ago
- Business
- Yahoo
EMX Announces Voting Results from its 2025 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - EMX Royalty Corporation (NYSE American: EMX) (TSXV: EMX) (the "Company" or "EMX") is pleased to report that all proposed resolutions were approved at the Company's Annual General Meeting of shareholders held on June 2, 2025, in Vancouver, British Columbia (the "Meeting"). The number of directors was set at 6 and all director nominees, as listed in the Management Information Circular dated April 15, 2025 (the "Information Circular"), were elected as directors of the Company at the Meeting to serve for a one-year term and hold office until the next annual meeting of shareholders. According to the proxy votes received from shareholders, the results were as follows: Director Votes FOR Votes WITHHELD Dawson C. Brisco 99.41% 0.59% David M. Cole 99.55% 0.45% Sunny S.C. Lowe 96.88% 3.12% Henrik K.B. Lundin 99.34% 0.66% Geoff G. Smith 99.52% 0.48% Michael D. Winn 99.51% 0.49% Shareholders voted 99.14% in favour of setting the number of directors at six, 99.10% in favour of appointing Davidson & Company LLP, Chartered Accountants as auditors, and 96.76% in favour of ratifying and approving the Company's Stock Option Plan. Voting results for all resolutions noted above are reported in the Report on Voting Results as filed under the Company's SEDAR+ profile on June 2, 2025. About EMX. EMX is a precious and base metals royalty company. EMX's investors are provided with discovery, development, and commodity price optionality, while limiting exposure to risks inherent to operating companies. The Company's common shares are listed on the NYSE American Exchange and TSX Venture Exchange under the symbol "EMX". Please see for more information. For further information contact: David M. ColePresident and CEOPhone: (303) 973-8585 Dave@ Stefan WengerChief Financial OfficerPhone: (303) 973-8585SWenger@ Isabel BelgerInvestor Relations Phone: +49 178 4909039IBelger@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release To view the source version of this press release, please visit
Yahoo
3 days ago
- Business
- Yahoo
Vanadian Energy Announces Upcoming Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Vanadian Energy Corp. (TSXV: VEC.H) ("VEC" or the "Company"), announces that the Company's 2024 Annual General and Special Meeting of Shareholders (the "AGSM") will be held in-person at Suite 3123, 595 Burrard Street, Vancouver, BC V7X 1J1, on Thursday, June 26th, 2025 at 10:00 am Vancouver time. The Notice of Meeting, Management Information Circular and Form of Proxy related to the AGSM has been mailed to shareholders and can be found on the Company's website at and on SEDAR+ under VEC's issuer profile. At the Meeting, in addition to the regular annual business, shareholders will be asked to consider and approve a proposed debt settlement involving the issuance of 8,885,772 common shares at a deemed price of $0.16 per share to settle $1,421,724 in outstanding debt (the "Debt Settlement"), subject to TSX Venture Exchange approval. As the issuance exceeds 100% of the Company's current outstanding shares and will result in the creation of two new Control Persons, disinterested shareholder approval is required under Exchange policies. The Debt Settlement includes: Clive T. Johnson, director, to receive 3,341,856 shares in settlement of debt of $534,697, resulting in ownership of approximately 29.45% of the outstanding shares of the Company. Gordon Keep, director, through entities he controls, to receive 3,810,938 shares in settlement of debt of $609,750 (discounted by 25% from $813,000), resulting in ownership of approximately 29.34% of the outstanding shares of the Company. The debt settlements with Messrs. Johnson and Keep constitute related party transactions under MI 61-101 (the "Related Party Transactions"). The Related Party Transactions are exempt from the requirement to obtain a valuation in respect thereof under MI 61-101 pursuant to section 5.5(c) of MI 61-101 as the Company is not listed on specified markets. The Company is required to obtain minority shareholder approval for the Related Party Transactions pursuant to MI 61-101. Votes held by Messrs. Johnson, Keep, their affiliates, will be excluded from the votes. Additional details on the proposed Debt Settlement and the Related Party Transactions can be found in the Management Information Circular which has been mailed to shareholders and is available for viewing on SEDAR+ and on the Company's website. The Board of Directors (excluding the interested parties) has approved the Debt Settlement, which is intended to strengthen the Company's balance sheet. Completion remains subject to shareholder and Exchange approval. ABOUT VANADIAN ENERGY CORP. Vanadian Energy Corporation is an energy minerals focused company headed by an experienced team, well versed in mineral exploration and capital markets. The company is focused on the strategic acquisition, exploration, and development of high quality energy mineral properties in Canada and around the world. Vanadian Energy Corporation is building a leading vanadium focused resource company. ON BEHALF OF VANADIAN ENERGY CORP. "Marc Simpson" Marc SimpsonPresident and CEOVanadian Energy CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The foregoing information may contain forward-looking information relating to the future performance of the Company. Forward-looking information is subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, changes in world commodity markets or equity markets, the risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes, change in government and changes to regulations affecting the mining industry, and other risks and uncertainties detailed from time to time in the Company's filings with the Canadian securities administrators (available at Forward-looking statements are made based on various assumptions and on management's beliefs, estimates and opinions on the date the statements are made. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking information contained herein. The Company undertakes no obligation to update forward-looking statements if these assumptions, beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Unitholders of Venator Founders Alternative Fund Approve Change of the Investment Objective and the Name of the Fund
TORONTO , May 29, 2025 /CNW/ - Venator Founders Alternative Fund (the "Fund") is pleased to announce the voting results for its Special Meeting of Shareholders held on May 29, 2025 in Toronto, Ontario. The resolution to change the investment objective of the Fund and the associated changes of name, currency and the investment strategies of the Fund and other conforming changes voted upon are described in detail in the Company's Management Information Circular dated April 29, 2024 which is available at A total of 815,338.6433 units of the Fund were represented, being 50.38% of the Fund's issued and outstanding units as at the record date. Unitholders voted in favour of the matter brought before the Special Meeting, and the specific voting results were as follows: Resolution Votes For % For Votes Against % Against Change the Investment Objective and associated changes 815,338.6433 100 % 0 0 % We are pleased with the support received from our unitholders and look forward to implementing the new objective and strategy once we receive final approval from the OSC. About Venator Capital Management Ltd. Venator Capital Management Ltd. is a Toronto-based investment firm, founded in 2005, that strives to generate superior, risk-adjusted returns across its equity long/short, fixed income and quantitative Funds. Venator is registered with the Ontario Securities Commission as a Portfolio Manager, Investment Fund Manager and Exempt Market Dealer. For more information about Venator Capital Management Ltd. and our family of funds please visit SOURCE Venator Capital Management Ltd. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
4 days ago
- Business
- Cision Canada
Unitholders of Venator Founders Alternative Fund Approve Change of the Investment Objective and the Name of the Fund
TORONTO , May 29, 2025 /CNW/ - Venator Founders Alternative Fund (the " Fund") is pleased to announce the voting results for its Special Meeting of Shareholders held on May 29, 2025 in Toronto, Ontario. The resolution to change the investment objective of the Fund and the associated changes of name, currency and the investment strategies of the Fund and other conforming changes voted upon are described in detail in the Company's Management Information Circular dated April 29, 2024 which is available at A total of 815,338.6433 units of the Fund were represented, being 50.38% of the Fund's issued and outstanding units as at the record date. Unitholders voted in favour of the matter brought before the Special Meeting, and the specific voting results were as follows: We are pleased with the support received from our unitholders and look forward to implementing the new objective and strategy once we receive final approval from the OSC. About Venator Capital Management Ltd. Venator Capital Management Ltd. is a Toronto-based investment firm, founded in 2005, that strives to generate superior, risk-adjusted returns across its equity long/short, fixed income and quantitative Funds. Venator is registered with the Ontario Securities Commission as a Portfolio Manager, Investment Fund Manager and Exempt Market Dealer. For more information about Venator Capital Management Ltd. and our family of funds please visit SOURCE Venator Capital Management Ltd.
